EchoIQ (ASX: EIQ) — Company Overview, News & Financial Data
EchoIQ is a medical technology company focused on developing artificial intelligence tools for the early detection and diagnosis of structural heart disease.
EchoIQ
EchoIQ is a medical technology company focused on developing artificial intelligence tools for the early detection and diagnosis of structural heart disease. The company's flagship decision-support software, EchoSolv AS, utilizes algorithm-driven analysis of standard echocardiographic measurement datasets to identify patients suffering from severe aortic stenosis. By integrating directly into existing clinical workflows and electronic health records without requiring image analysis, the platform assists cardiologists and healthcare providers in diagnosing heart conditions, optimizing patient turnaround time, and improving clinical decision-making across healthcare networks in the United States and Australia.
Snapshot
Operations
Products and/or services of EchoIQ
- EchoSolv AS Diagnostic Software: FDA-cleared decision-support software that analyzes standard numerical echocardiographic measurement data to identify patients with severe aortic stenosis, integrating directly into existing healthcare workflows without requiring image analysis or full video processing.
- Structural Heart Disease Decision Support: Artificial intelligence algorithms designed to evaluate multidimensional echocardiography data to assist clinicians in detecting various structural heart conditions, identifying high-risk patients, and standardizing clinical decision-making in hospital cardiology departments.
- EHR and Workflow Integration Solutions: Software integration services that embed automated measurement analysis platforms into hospital electronic health records, picture archiving and communication systems, and reporting tools to streamline patient triage and diagnostic turnaround times.
- Echocardiographic Data Analytics and Research: Analytical services utilizing a proprietary database of over 200 million echocardiographic measurements to support ongoing clinical research, algorithm development, and validation studies alongside medical research institutions and healthcare providers.
EchoIQ executive team
- Andrew Richard GroverExecutive Chairman
- Dustin HainesChief Executive Officer
- Matthew Joseph Dodds IIIChief Financial Officer
- Patrick O'SheaHead of Strategy & Operations
- Sam DribinChief Technology Officer
- David PlayfordChief Medical Advisor
- Deon StrydomChief Commercial Officer
- Geoffrey A. StrangeChief Research & Strategy Officer
- Dane BrescacinSVP of Regulatory Affairs
- Jessamyn Sarah LyonsCompany Secretary & Director
Latest news about EchoIQ
Echo IQ addresses FDA feedback on EchoSolv HF
AustraliaEcho IQ inks data licensing agreement with Advara HeartCare
AustraliaEcho IQ raises $110M in institutional placement
AustraliaEcho IQ signs $20M Pro Medicus deal
AustraliaEcho IQ partners with Mayo Clinic for AI study
AustraliaEcho IQ expands Mayo Clinic heart AI partnership
Australia
Recent announcements
What EchoIQ (EIQ) has told the market, newest first.
- EchoSolv HF FDA 510(k) updatePrice sensitive
- Date of AGM and Closing Date for Director Nominations
- Updated Securities Trading Policy
Key financials
Reported results for EchoIQ, in AUD.
- Market cap
- 359.3M
- Revenue (TTM)
- 92K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 92K | -19.8M | -18.6M | |
| 101.4K | -13M | -13.3M | |
| 44.5K | -5.9M | -5.4M | |
| 107.3K | -7M | -8.3M |